Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Short-term discontinuation of HAART regimens more common in vulnerable patient populations.

Robison LS, Westfall AO, Mugavero MJ, Kempf MC, Cole SR, Allison JJ, Willig JH, Raper JL, Wilcox CM, Saag MS.

AIDS Res Hum Retroviruses. 2008 Nov;24(11):1347-55. doi: 10.1089/aid.2008.0083.

2.

Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.

Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi EM, Antinori A, Gatti F, Cassola G, Sighinolfi L, Castelli P, d'Arminio Monforte A; ICoNA Foundation Study Group..

HIV Med. 2010 Feb;11(2):104-13. doi: 10.1111/j.1468-1293.2009.00750.x.

3.

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.

d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U, Moroni M.

AIDS. 2000 Mar 31;14(5):499-507.

PMID:
10780712
4.
5.

[First antiretroviral therapy regimen in HIV-infected patients. Durability and factors associated with therapy changes].

de la Torre J, Santos J, Perea-Milla E, Pérez I, Moreno F, Palacios R, Santamaría S, Del Arco A, Nuño E, Godoy M, Prada JL, Olalla J, Aguilar J, Martos F; Grupo Malagueño de Enfermedades Infecciosa..

Enferm Infecc Microbiol Clin. 2008 Aug-Sep;26(7):416-22. Spanish.

PMID:
18842236
6.

Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.

Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, Boron-Kaczmarska A, Viksna L, Kirk O, Lundgren JD; EuroSIDA Study Group..

AIDS Res Hum Retroviruses. 2005 Sep;21(9):743-52.

PMID:
16218797
7.

Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort.

O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P.

J Acquir Immune Defic Syndr. 2003 Dec 1;34(4):407-14.

PMID:
14615659
8.

Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy among HIV-infected women, 2005.

Lillie-Blanton M, Stone VE, Snow Jones A, Levi J, Golub ET, Cohen MH, Hessol NA, Wilson TE.

Am J Public Health. 2010 Aug;100(8):1493-9. doi: 10.2105/AJPH.2008.158949.

9.

Effects of pill burden on discontinuation of the initial HAART regimen in minority female patients prescribed 1 pill/day versus any other pill burden.

Hill S, Kavookjian J, Qian J, Chung A, Vandewaa J.

AIDS Care. 2014;26(5):595-601. doi: 10.1080/09540121.2013.844766.

PMID:
24111921
10.

The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women.

Anastos K, Schneider MF, Gange SJ, Minkoff H, Greenblatt RM, Feldman J, Levine A, Delapenha R, Cohen M; Women's Interagency HIV Study Collaborative Group..

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):537-44.

PMID:
16044004
11.

Virologic success in an urban HIV clinic: outcome at 12 months in patients who were HAART naïve.

Blanchard E, Klibanov OM, Axelrod P, Palermo B, Samuel R.

HIV Clin Trials. 2008 May-Jun;9(3):186-91. doi: 10.1310/hct0903-186.

PMID:
18547905
12.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
13.

Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy.

Chao C, Tang B, Hurley L, Silverberg MJ, Towner W, Preciado M, Horberg M.

AIDS Res Hum Retroviruses. 2012 Dec;28(12):1630-6. doi: 10.1089/AID.2012.0005.

14.

A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.

Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, Viard JP, Gatell J, Blaxhult A, Lundgren JD.

J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):369-78.

PMID:
10634199
15.

Changes in sexual and drug-related risk behavior following antiretroviral therapy initiation among HIV-infected injection drug users.

Fu TC, Westergaard RP, Lau B, Celentano DD, Vlahov D, Mehta SH, Kirk GD.

AIDS. 2012 Nov 28;26(18):2383-91. doi: 10.1097/QAD.0b013e32835ad438.

16.

Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals.

Greenbaum AH, Wilson LE, Keruly JC, Moore RD, Gebo KA.

AIDS. 2008 Nov 12;22(17):2331-9. doi: 10.1097/QAD.0b013e32831883f9.

17.

The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.

Sabin CA, Smith CJ, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C, Gazzard B, Porter K, Mackie N, Fisher M, Orkin C, Johnson M, Easterbrook P, Hill T, Phillips AN; UK Collaborative HIV Cohort (CHIC) Study..

HIV Med. 2009 Jan;10(1):35-43. doi: 10.1111/j.1468-1293.2008.00654.x.

18.

Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors.

Kiguba R, Byakika-Tusiime J, Karamagi C, Ssali F, Mugyenyi P, Katabira E.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):218-23.

PMID:
17438478
19.

Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.

Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, Boron-Kaczmarska A, Viksna L, Kirk O, Lundgren JD; EuroSIDA Study Group..

AIDS Res Hum Retroviruses. 2005 Jun;21(6):527-36.

PMID:
15989457
20.
Items per page

Supplemental Content

Support Center